A Novel Formulation Strategy to Deliver Combined DNA and VLP Based HPV Vaccine

Human papillomaviruses (HPV) are small, double-stranded DNA viruses that cause cervical cancer, the second most lethal cancer among women in the world. Currently, two vaccines are on the market for preventing HPV-caused cervical cancers and warts. Both are virus-like particle (VLP)-based vaccines. H...

Full description

Bibliographic Details
Main Authors: Mohammad Nasir Uddin, Brittany Henry, Kewan D Carter, Monzurul a Roni, Samir S Kouzi
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Journal of Pharmacy & Pharmaceutical Sciences
Online Access:https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/30768
_version_ 1797701574280085504
author Mohammad Nasir Uddin
Brittany Henry
Kewan D Carter
Monzurul a Roni
Samir S Kouzi
author_facet Mohammad Nasir Uddin
Brittany Henry
Kewan D Carter
Monzurul a Roni
Samir S Kouzi
author_sort Mohammad Nasir Uddin
collection DOAJ
description Human papillomaviruses (HPV) are small, double-stranded DNA viruses that cause cervical cancer, the second most lethal cancer among women in the world. Currently, two vaccines are on the market for preventing HPV-caused cervical cancers and warts. Both are virus-like particle (VLP)-based vaccines. However, these vaccines have limitations; they are costly, have an invasive route of administration, require trained personnel to administer, need cold chain storage to preserve them, and most of all, they are preventive vaccines that do not have curative effects. Therefore, it is necessary to develop therapeutic HPV vaccines to facilitate the control of HPV-associated malignancies and to address all these issues. Recently there are DNA vaccines under investigation to prevent HPV. In general, DNA-based vaccines are better than or an excellent alternative to traditional vaccines since they can closely mimic live infections and can induce both antibody and cell-mediated immune responses. DNA vaccines involve the delivery of plasmid DNA (pDNA) which encodes the specific antigens. DNA vaccines have potential to be effective therapeutic tools against HPV infections. Combining the VLP-based and DNA-based vaccines can be highly effective as they can complement each other. VLP vaccines are more prone to mucosal immunity whereas DNA vaccines are more towards systemic immunity. In this article, we discuss an optimal formulation that will contain both type of vaccines, preventive and therapeutic. A film dosage form can be a good option which can be administered in buccal or sublingual routes for systemic action or in the vaginal area for local action to treat cervical cancer and to protect from future infection. Multiple vaccines in native form or in particulate form can be incorporated in film dosage forms. The film dosage form of vaccines can elicit both antibody-mediated (preventative) and cell-mediated (therapeutic) mechanisms. Film dosage forms are feasible to prepare for vaccine administration in the mouth cavity, GI tract, and vagina.
first_indexed 2024-03-12T04:38:39Z
format Article
id doaj.art-0b72598b0b324782b9ac1c1bbf4131c1
institution Directory Open Access Journal
issn 1482-1826
language English
last_indexed 2024-03-12T04:38:39Z
publishDate 2019-11-01
publisher Frontiers Media S.A.
record_format Article
series Journal of Pharmacy & Pharmaceutical Sciences
spelling doaj.art-0b72598b0b324782b9ac1c1bbf4131c12023-09-03T09:49:51ZengFrontiers Media S.A.Journal of Pharmacy & Pharmaceutical Sciences1482-18262019-11-0122110.18433/jpps30768A Novel Formulation Strategy to Deliver Combined DNA and VLP Based HPV VaccineMohammad Nasir Uddin0Brittany Henry1Kewan D Carter2Monzurul a Roni3Samir S Kouzi4College of Pharmacy, Larkin University, Miami, FL 33169. 2. University of Illinois College of Medicine, Peoria, IL 61605.College of Pharmacy, Larkin University, Miami, FL 33169. 2. University of Illinois College of Medicine, Peoria, IL 61605.College of Pharmacy, Larkin University, Miami, FL 33169. 2. University of Illinois College of Medicine, Peoria, IL 61605.Levine College of Health Sciences, Wingate University, Wingate, NC 28174.Levine College of Health Sciences, Wingate University, Wingate, NC 28174.Human papillomaviruses (HPV) are small, double-stranded DNA viruses that cause cervical cancer, the second most lethal cancer among women in the world. Currently, two vaccines are on the market for preventing HPV-caused cervical cancers and warts. Both are virus-like particle (VLP)-based vaccines. However, these vaccines have limitations; they are costly, have an invasive route of administration, require trained personnel to administer, need cold chain storage to preserve them, and most of all, they are preventive vaccines that do not have curative effects. Therefore, it is necessary to develop therapeutic HPV vaccines to facilitate the control of HPV-associated malignancies and to address all these issues. Recently there are DNA vaccines under investigation to prevent HPV. In general, DNA-based vaccines are better than or an excellent alternative to traditional vaccines since they can closely mimic live infections and can induce both antibody and cell-mediated immune responses. DNA vaccines involve the delivery of plasmid DNA (pDNA) which encodes the specific antigens. DNA vaccines have potential to be effective therapeutic tools against HPV infections. Combining the VLP-based and DNA-based vaccines can be highly effective as they can complement each other. VLP vaccines are more prone to mucosal immunity whereas DNA vaccines are more towards systemic immunity. In this article, we discuss an optimal formulation that will contain both type of vaccines, preventive and therapeutic. A film dosage form can be a good option which can be administered in buccal or sublingual routes for systemic action or in the vaginal area for local action to treat cervical cancer and to protect from future infection. Multiple vaccines in native form or in particulate form can be incorporated in film dosage forms. The film dosage form of vaccines can elicit both antibody-mediated (preventative) and cell-mediated (therapeutic) mechanisms. Film dosage forms are feasible to prepare for vaccine administration in the mouth cavity, GI tract, and vagina.https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/30768
spellingShingle Mohammad Nasir Uddin
Brittany Henry
Kewan D Carter
Monzurul a Roni
Samir S Kouzi
A Novel Formulation Strategy to Deliver Combined DNA and VLP Based HPV Vaccine
Journal of Pharmacy & Pharmaceutical Sciences
title A Novel Formulation Strategy to Deliver Combined DNA and VLP Based HPV Vaccine
title_full A Novel Formulation Strategy to Deliver Combined DNA and VLP Based HPV Vaccine
title_fullStr A Novel Formulation Strategy to Deliver Combined DNA and VLP Based HPV Vaccine
title_full_unstemmed A Novel Formulation Strategy to Deliver Combined DNA and VLP Based HPV Vaccine
title_short A Novel Formulation Strategy to Deliver Combined DNA and VLP Based HPV Vaccine
title_sort novel formulation strategy to deliver combined dna and vlp based hpv vaccine
url https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/30768
work_keys_str_mv AT mohammadnasiruddin anovelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine
AT brittanyhenry anovelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine
AT kewandcarter anovelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine
AT monzurularoni anovelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine
AT samirskouzi anovelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine
AT mohammadnasiruddin novelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine
AT brittanyhenry novelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine
AT kewandcarter novelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine
AT monzurularoni novelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine
AT samirskouzi novelformulationstrategytodelivercombineddnaandvlpbasedhpvvaccine